Valuation: Geron Corporation

Market Cap 885M 774M 715M 661M 1.24B 85.04B 1.27B 8.53B 3.35B 41.64B 3.33B 3.25B 143B P/E 2026 *
-69x
P/E 2027 * 21.8x
Enterprise Value 864M 755M 698M 645M 1.21B 83.02B 1.24B 8.33B 3.27B 40.65B 3.25B 3.17B 140B EV / Sales 2026 *
3.7x
EV / Sales 2027 * 2.15x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.82%
1 week-7.38%
Current month+7.81%
1 month+20.00%
3 months-22.03%
6 months+2.22%
Current year+4.55%
1 week 1.35
Extreme 1.35
1.62
1 month 1.14
Extreme 1.14
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

6,103 0.0010%
05-20Free

Director

220,000 0.0343%
05-20Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-2.82%-7.38%+2.99%-57.14% 885M
+0.21%-6.28%+56.18%+127.90% 54.49B
+6.05%+7.79%+62.23%+88.46% 55.93B
+0.89%-2.42%+8.07%+434.51% 23.87B
+0.37%-4.13%-18.56%-16.48% 22.86B
+5.39%+12.90%+47.47%-1.44% 20B
-2.29%-1.92%+35.57%-29.14% 17.48B
-4.00%-10.96%+181.91%+328.17% 15.39B
+10.90%+15.25%+54.50%+745.45% 15.19B
-0.48%-2.30%+22.36%+187.62% 14.02B
Average +1.42%-2.38%+45.27%+180.79% 24.01B
Weighted average by Cap. +2.26%-0.52%+49.25%+167.96%

Financials

2026 *2027 *
Net sales 234M 204M 189M 175M 329M 22.46B 335M 2.25B 884M 11B 878M 859M 37.87B 333M 291M 269M 249M 468M 32B 477M 3.21B 1.26B 15.67B 1.25B 1.22B 53.95B
Net income -13.87M -12.12M -11.21M -10.35M -19.5M -1.33B -19.85M -134M -52.43M -652M -52.1M -50.95M -2.25B 46.53M 40.66M 37.59M 34.73M 65.4M 4.47B 66.59M 448M 176M 2.19B 175M 171M 7.54B
Net Debt -20.97M -18.32M -16.94M -15.65M -29.47M -2.01B -30.01M -202M -79.26M -986M -78.76M -77.02M -3.4B -169M -148M -137M -126M -238M -16.23B -242M -1.63B -639M -7.95B -635M -621M -27.37B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
14/07/26 US$1.380 -2.82% 11,736,079
13/07/26 US$1.420 -5.33% 7,162,331
10/07/26 US$1.500 -3.85% 10,348,929
09/07/26 US$1.560 0.00% 11,741,658
08/07/26 US$1.560 +4.70% 13,532,895
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.380USD
Average target price
3.400USD
Spread / Average Target
+146.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock